Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment.
Efficacy ofCECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial.
AI Summary
Key Findings
Abstract
Infantile colic is a prevalent condition characterised by excessive crying with no effective treatment available. We aimed to evaluate the efficacy ofCECT7263 and a combination of this andCECT5716 versus simethicone in reducing the daily time spent crying in colicky infants. A multicentre randomised, open-label, parallel, controlled trial of 28 days was performed in 150 infants who were diagnosed with colic according to the Rome III criteria and who randomly received simethicone (80 mg/day; Simethicone group),CECT7263 (2×10cfu/day, Bb group), or a combination ofCECT5716 andCECT7263 (1×10cfu/day per strain, Bb+Lf group). The main outcomes were minutes of crying per day and the percentage of reduction in daily crying from baseline. Data were analysed per intention to treat. All treatments significantly decreased the daily crying time at the end of the intervention (-time
Affiliation
J A Maldonado-Lobón
External References
- PubMed ID:
- 33350361
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.